Mbs

Telehealth Prescribing of Schedule 4 Peptides in Australia: 2026 Policy Brief

Telehealth has become a permanent fixture of Australian healthcare. Its intersection with Schedule 4 peptide prescribing — covering agents like semaglutide, tirzepatide, and emerging research peptides — remains under-examined. This brief surveys the current regulatory framework, identifies oversight gaps, and proposes reform priorities to ensure clinical safety without restricting legitimate access.